

# Continuing Pharmacy Education

Thursday, March 9, 2016

**8 Unique Topics**

**\*\*Up to three (3) COMPLIMENTARY CE credits per attendee\*\***

**Time:** 3:15 - 4:00 PM Pre-registration check-in  
4:00 - 7:00 PM CE Programs

**Location:** McNeil Science Center  
Philadelphia College of Pharmacy  
Philadelphia, PA

*These activities are designed for pharmacists.*

**General Pharmacy:**

Pharmacists Prescribing Oral Contraceptives: Regulatory and Controversial Impact

**Dr. Nisha Parikh**

(UAN: 0056-0000-17-007-L04-P)

Pharmacists' Role in Dispensing Naloxone for Opioid Abuse

**Dr. Sona Doshi**

(UAN: 0056-0000-17-012-L04-P)

What is Pharmacovigilance and Why Do We Need It?

**Dr. Mehul Desai**

(UAN: 0056-0000-17-009-L04-P)

**Drug Therapy:**

Retain the Brain: Acute Ischemic Stroke Update

**Dr. Hayley Kavalek**

(UAN: 0056-0000-17-011-L01-P)

Immune Checkpoint Inhibitors: Releasing the Immunologic Brakes on Cancer

**Dr. Vanesha Patel**

(UAN: 0056-0000-17-008-L01-P)

The Superheroes of Gram-negative Bacteria

**Dr. Brooklyn Cobb**

(UAN: 0056-0000-17-014-L01-P)

**Patient Safety:**

Management of Severe Bleeding Caused by Oral Anticoagulation

**Dr. Julianne Knecht**

(UAN: 0056-0000-17-006-L05-P)

**Pharmacy Law:**

Patents and Exclusivity: Updates on the Biosimilar Litigation Revolution

**Dr. Rachel Brown**

(UAN: 0056-0000-17-005-L03-P)



The Philadelphia College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Activity	Faculty Member	Credits	Learning Objectives
<b>Pharmacist Prescribing of Hormonal Contraceptives: Regulatory and Controversial Impact</b>  Knowledge-based	Dr. Nisha Parikh	1 hour	<ol style="list-style-type: none"> <li>1. Discuss the rationale for allowing pharmacists to prescribe oral contraceptives.</li> <li>2. Identify the current state and legislative decisions that approved oral contraceptive prescribing by pharmacists.</li> <li>3. Describe the potential impact of current regulations on the United States healthcare system.</li> <li>4. Summarize the controversy surrounding this legislation and its influence on patient care.</li> </ol>
<b>Pharmacists' Role in Dispensing Naloxone for Opioid Abuse</b>  Knowledge-based	Dr. Sona Doshi	1 hour	<ol style="list-style-type: none"> <li>1. Recall the incidence, prevalence and death rates of opioid abuse in the Philadelphia region.</li> <li>2. Identify the mechanism behind opioid addiction</li> <li>3. Discuss the role of naloxone in opioid overdose</li> <li>4. Review the standing order principle for naloxone in Pennsylvania</li> </ol>
<b>What is Pharmacovigilance and Why Do We Need It?</b>  Knowledge-based	Dr. Mehul Desai	1 hour	<ol style="list-style-type: none"> <li>1. Differentiate between responsible parties and drug registries in event reporting</li> <li>2. Discuss how patient reported outcomes and social media serve as a source of event data</li> <li>3. Explain the process of event reporting and how it impacts product labeling</li> <li>4. Describe the impact of event reporting on clinical outcomes</li> </ol>
<b>Retain the Brain: Acute Ischemic Stroke Updates</b>  Knowledge-based	Dr. Hayley Kavelakl	1 hour	<ol style="list-style-type: none"> <li>1. Discuss the eligibility standards and requirements for primary stroke centers, comprehensive stroke centers, and stroke-ready hospitals.</li> <li>2. Describe the pathophysiology of acute ischemic stroke.</li> <li>3. Determine the appropriate use of alteplase in the setting of acute ischemic stroke.</li> <li>4. Evaluate the literature supporting the AHA/ASA updated inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke.</li> <li>5. Recommend an evidence-based treatment strategy for a patient with acute ischemic stroke.</li> </ol>
<b>Immune Checkpoint Inhibitors: Releasing the Immunologic Brakes on Cancer</b>  Knowledge-based	Dr. Vanesha Patel	1 hour	<ol style="list-style-type: none"> <li>1. Identify the role of immunotherapy in the treatment of cancer</li> <li>2. Describe how immune checkpoint inhibitors target different types of cancer</li> <li>3. Discuss the currently approved agents and their indications for use</li> <li>4. Identify strategies for managing the side effects associated with immune checkpoint inhibitors</li> </ol>
<b>The Superheroes of Gram-Negative Bacteria</b>  Knowledge-based	Dr. Brooklyn Cobb	1 hour	<ol style="list-style-type: none"> <li>1. Describe the mechanism and spectrum of resistance for gram-negative bacteria that produce CRE and MDR pseudomonas.</li> <li>2. Evaluate potential treatment options for CRE including ceftazidime-avibactam and meropenem-vaborbactam.</li> <li>3. Evaluate potential treatment options for MDR pseudomonas including ceftolozane-tazobactam.</li> <li>4. Assess evidence-based treatment options given a patient case for CRE.</li> </ol>
<b>Management of Severe Bleeding Caused by Oral Anticoagulation</b>  Knowledge-based	Dr. Julianne Knecht	1 hour	<ol style="list-style-type: none"> <li>1. Identify medications commonly associated with adverse events in hospitalized or ambulatory patients that can lead to emergency department visits</li> <li>2. Name the coagulation cascade site(s) of action for warfarin, apixaban, dabigatran, edoxaban, and rivaroxaban</li> <li>3. Describe the mechanism of action of idarucizumab and andexanet for reversing anticoagulant-associated bleeding</li> <li>4. Apply current practice guidelines to manage a patient case of major bleeding associated with warfarin, apixaban, dabigatran, edoxaban, or rivaroxaban</li> </ol>
<b>Patents and Exclusivity: Updates on the Biosimilar Litigation Revolution</b>  Knowledge-based	Dr. Rachel Brown	1 hour	<ol style="list-style-type: none"> <li>1. Summarize the impact of patents and exclusivity on biosimilar regulatory pathway timelines</li> <li>2. Explain the patent dispute procedure, commonly referred to as the "patent dance," established by the Biologics Price Competition and Innovation Act (BCPI Act) of 2009</li> <li>3. Discuss prominent biosimilar patent litigation suits and how they may impact future biosimilar development</li> </ol>

**Fee Information:** There is not a fee for these educational activities.

**Financial Support:** These programs have not received any financial support.

**To obtain credit:**

For successful completion of the program and eligibility for credit, the participant must be present for the entire program to receive a program “claiming code”. In order to obtain credit for this program, please enter the claiming code into the PCP CECENTER website <https://www.highmarksce.com/pcp/> to register and complete the online program evaluation and learning assessment exam. A score of 70% or higher, with a maximum of 3 attempts, is required to claim credit.

Submission of learning assessments and program evaluations must be completed within 30 days of the program to receive continuing education credit.

NOTE: It may take up to 4 weeks for credits to be processed and available on CPE Monitor